TABLE 1.

Antiviral activities^a of NCINIs and INSTIs against HIV-1_LAI and HIV-1_NL4-3 and cytotoxicities^b

Drug	Mean EC50 (μM) ± SD		Mean CC50 (μM) ± SD
	MT-2 cells with HIV-1LAI	MT-4 cells with HIV-1NL4-3	MT-4 cells	HEK293T cells
NCINI-1	2.29 ± 1.19	7.01 ± 5.41	42.23 ± 9.44	34.26 ± 4.19
NCINI-2	0.77 ± 0.13	2.60 ± 0.34	66.59 ± 1.70	>100
NCINI-3	0.029 ± 0.003	0.19 ± 0.13	45.67 ± 6.17	>100
NCINI-4	0.032 ± 0.001	0.027 ± 0.004	36.09 ± 1.59	>100
RAL	0.0024 ± 0.0012	0.0019 ± 0.0008	>100	>100
EVG	0.0019 ± 0.0020	0.0036 ± 0.0002	2.89 ± 0.59	4.19 ± 3.89
DTG	0.0010 ± 0.0010	0.0029 ± 0.0010	14.33 ± 0.64	21.39 ±0.97

^aMT-2 cells were exposed to 100 TCID₅₀s of HIV-1_LAI and cultured in the presence of various concentrations of NCINIs and INSTIs, and EC₅₀s were determined by using an MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] assay.

^bCytotoxicities (CC₅₀s) of NCINIs and INSTIs against MT-4 and HEK293T cells were also determined by an MTT assay. All assays were conducted in duplicate, and data shown represent mean values ± SD from three independent experiments.